Pharma BD Deal Intelligence
Continuing its global deal-making spree, Sanofi-Aventis has forged a deal to buy San Diego-based TargeGen for $75 million down and up to $560 million in…
The ultimate purchase price for TargeGen will depend on the achievement of certain milestones with the potential of reaching $560 million — factual wire-style…
Sanofi continued fedratinib development from 2010 until 2013 when it was discontinued; rights moved to Impact Biomedicines (2016) and Celgene (2018), with FDA…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Sanofi-Aventis to acquire TargeGen with $75M upfront + milestones up to $485M (total $560M). Adds JAK2 inhibitor TG101348 for myelofibrosis.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / TargeGen, Inc. (this deal) | 2010 | $560M | 33 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2010 deals · Sanofi SA deals · Hematology deals